A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

drug protocol number
MOR-004
drug sponsor
BioMarin Pharmaceutical Inc.
drug study
BMN 110
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Completed
drug phase